
https://www.science.org/content/blog-post/where-drugs-come-country
# Where Drugs Come From: By Country (November 2010)

## 1. SUMMARY
This article analyzes 1998-2007 drug approval data from a Nature Reviews Drug Discovery paper, examining the geographic origins of new drugs and patterns of pharmaceutical innovation. The key findings show that the United States discovered nearly half (118 of 252) of all approved drugs during this period, roughly proportional to its market share. However, the US stood out as a major outlier in innovation quality—while most countries (especially Japan and Germany) focused heavily on "follow-on" or "me-too" drugs with existing mechanisms, US-discovered drugs were predominantly first-in-class medicines addressing unmet medical needs and receiving FDA priority review.

The most striking difference identified was the role of biotechnology companies: 60% of US drugs bore "fingerprints of biotech companies," either through direct development or licensing from universities. In contrast, other countries' drug pipelines were overwhelmingly dominated by traditional pharmaceutical companies. The UK and Switzerland also outperformed relative to their market size, but the US remained distinctive in producing both the quantity and quality of innovation. The article concludes that the US biotech industry served as the primary global driver of innovative drug discovery during this decade.

## 2. HISTORY
The trends identified in this 2010 analysis largely persisted and evolved over the subsequent decade, though with some important shifts:

**Continued US Leadership with Some Erosion**: The US maintained its position as the dominant source of new drug discoveries throughout the 2010s, but other regions—particularly China—began to emerge. By 2018-2022, analysis of new drug approvals showed the US still leading but with China increasingly represented in discovery efforts, particularly for certain therapeutic areas. The biotechnology ecosystem in China expanded dramatically, though it would take until the late 2010s for Chinese-discovered drugs to appear in significant numbers in FDA approvals.

**Biotech's Continued Central Role**: The 60% biotech involvement figure identified for the US during 1998-2007 remained characteristic of American drug discovery. Throughout the 2010s, small and medium biotech companies continued to originate a majority of innovative drugs, which were then either developed independently or acquired/licensed by larger pharmaceutical companies. This contrasted with other regions where traditional Big Pharma maintained tighter control over discovery pipelines.

**Germany and Japan's Innovation Evolution**: While characterized in 2010 as "kings of follow-ons," both countries made deliberate efforts to increase innovative drug discovery. Japan's PMDA reforms and increased translational research funding began bearing fruit, with more first-in-class drugs emerging from Japanese companies by the mid-2010s. However, these regions still lagged the US in biotech-driven innovation ecosystems.

**Policy and Regulatory Impacts**: FDA priority review, which the article noted disproportionately favored US drugs, became an even more important innovation indicator. The 2012 FDA Safety and Innovation Act (FDASIA) and subsequent PDUFA reauthorizations maintained this system. Real-world uptake did correlate with priority review status, with first-in-class drugs generally achieving favorable market adoption when they addressed genuine unmet needs.

**University Technology Transfer Maturation**: US university tech transfer continued to be a significant but minority source of drug candidates, typically maintaining the innovative character noted in the article. However, no major shift toward universities operating "profitable drug-discovery businesses" occurred; instead, the model remained licensing to established companies.

## 3. PREDICTIONS
The article made limited explicit predictions about the future, but contained these forecast-like statements and implicit expectations:

• **"I confidently predict that we'll see more follow-on drugs from [universities] as well"** (if universities deliberately pursued profitable drug discovery)
  - **Outcome**: This did not materialize as a major trend. Universities continued to focus on basic research and early-stage innovation, with follow-on drug development remaining primarily the domain of established pharmaceutical companies. No significant shift toward universities developing me-too drugs occurred.

• **Implicit expectation that American exceptionalism in drug discovery would continue**
  - **Outcome**: Broadly accurate through the 2010s, though with increased competition from other regions, particularly China's emergence as a biotech hub in the late 2010s. US innovation leadership persisted but the gap narrowed somewhat.

• **Implicit prediction that biotech-derived drug trends would continue**
  - **Outcome**: Accurate. Biotech companies remained central to US drug innovation throughout the subsequent decade, with this ecosystem continuing to differentiate the US from other regions.

## 4. INTEREST
**Rating: 7**

This analysis captured a critical period in pharmaceutical globalization and provided empirically-grounded insights about the structural advantages of the US biotech ecosystem. The article's lasting value comes from documenting the inflection point when geographic drug discovery patterns began shifting, making it historically significant for understanding innovation dynamics that persisted through the 2010s.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20101109-where-drugs-come-country.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_